Agenda

OFFICIALLY LICENSED
BEST OF ASCO®
2019 ANNUAL MEETING

Lo mejor de la Sociedad Americana de Oncología Clínica en Panamá
Friday, July 26

7:00am - 8:30 am:     Breakfast – Satellite Event
                        Conferences (Riu Plaza Hotel)

8:30am - 8:45am:     Welcome and Chair Remarks
                        Gaspar Perez Jimenez, M.D. FACP
                        President of the Panamanian Society of Oncology

8:45am – 9:30am:     Gastrointestinal Cancer (Colorectal)
                        David H. Ilson, MD. PhD
                        Memorial Sloan Kettering Cancer Center

Abstract 3501: Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months (m)) for patients (pts) with high-risk stage II colorectal cancer (CC).

Abstract 3504: FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

Abstract LBA 3506: BEACON CRC: A randomized, three-arm, phase III study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BINI) versus the choice of either irinotecan (IRI) or FOLFIRI plus CETUX in patients (Pts) with BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Abstract 3508: Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

9:30am - 10:15am:    Gastrointestinal Cancer (Non-colorectal)
                        David H. Ilson, MD. PhD
                        Memorial Sloan Kettering Cancer Center

Abstract LBA 4: Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC); Phase III POLO trial.

Abstract 4000: APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs. gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Abstract 4003: ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+MFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

10:15am - 10:45am:   Break (Foyer)

Conferences (Riu Plaza Hotel)

10:45am – 11:30am:   Lung Cancer NSCLC– Local/Regional, Small Cells and others Thoracic Cancers.
                        George R. Simon MD. FACP, FCCP
                        The University of Texas MD Anderson Cancer Center

Abstract 8502: Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).

Abstract 8503: Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Abstract 8504: Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

Abstract 8506: Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

11:30am – 12:15pm:   Lung Cancer NSCLC– Metastatic
                        George R. Simon MD. FACP, FCCP
                        The University of Texas MD Anderson Cancer Center

Abstract 900: RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Abstract 9001: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).

Abstract 9002: ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

Abstract 9016: Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
12:15pm – 1:45pm: Lunch – Satellite Event

1:45pm - 2:30pm: Head and Neck Cancer
David Adelstein, MD, FACP
Cleveland Clinic Taussig Cancer Institute

Abstract 6000: Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Abstract 6002: TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Abstract 6003: Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

Abstract 6015: Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

2:30pm – 3:15pm: Melanoma / Skin Cancer non Melanoma
Kevin B Kim, MD.
California Pacific Medical Center

Abstract 2512: Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

Abstract 9500: Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).

Abstract 9501: Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).


Abstract 9507: Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

7:00pm. - 9:00pm. Dinner - Satellite Event
7:15am - 8:45am: Break – Satellite Event
Conferences (Riu Plaza Hotel)

8:45am – 9:30am: Breast Cancer – Local/Regional/Adjuvant
Vicente Valero, MD, FACP
The University of Texas MD Anderson Cancer Center

Abstract 503: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

Abstract 504: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).

Abstract 508: Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RT06 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.

9:30am – 10:15am: Breast Cancer – Metastatic
Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center

Abstract 1000: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

Abstract 1002: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Abstract 1003: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Abstract 1008: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2– advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

10:15am - 10:45am: Break (Foyer)
Conferences (Riu Plaza Hotel)

10:45am – 11:30am: Genitourinary Cancer (Prostate)
Primo Nery Lara, Jr., M.D.
UC Davis Comprehensive Cancer Center

Abstract LBA2: Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

Abstract 5006: First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Abstract 5007: Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.

Abstract 5008: Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).

11:30am - 12:15pm: Genitourinary Cancer (Non-prostate)
Primo Nery Lara, Jr., M.D.
UC Davis Comprehensive Cancer Center

Abstract 4500: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.

Abstract 4503: CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

Abstract 4504: Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.

Abstract 4505: EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
Saturday, July 27

12:15pm - 1:00pm:  Gynecological Cancer
Dana Chase, MD
The University of Arizona Cancer Center

Abstract 5500: A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.


Abstract 5506: Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

Abstract 5508: EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

1:00pm – 2:00pm:  Lunch – Satellite Event